Recombinant production of human ICAM-1 chimeras by single step on column 2 refolding and purification by Núñez Jurado, David et al.
Page 1 of 33
Ac
ce
pte
d M
an
us
cri
pt
Recombinant production of human ICAM-1 chimeras by single step on column 1
refolding and purification.2
David Núñez1,2, María Pilar Domingo1,2, Diego Sánchez-Martínez2,3, Vicente Cebolla1, 3
Arthur Chiou4, Adrián Velázquez-Campoy3,5,6, Julián Pardo2,3,6,7‡ and Eva Mª 4
Gálvez1,2*‡5
1 Instituto de Carboquímica ICB-CSIC, Zaragoza, Spain6
2 Immune Effector Cells Group, Aragón Health Research Institute (IIS Aragón), 7
Biomedical Research Centre of Aragón (CIBA)8
3 Dpt. Biochemistry and Molecular and Cell Biology, Fac. Ciencias, University of 9
Zaragoza, Zaragoza, Spain 10
4 Institute of Biophotonics, National Yang-Ming University, Taipei, Taiwan11
5 Institute of Biocomputation and Physics of Complex Systems (BIFI), Unidad 12
Asociada IQFR-CSIC-BIFI, Universidad de Zaragoza, Zaragoza, Spain.13
6 Aragón I+D Foundation (ARAID), Government of Aragon, Zaragoza, Spain14
7 Nanoscience Institute of Aragon (INA). Aragón I+D Foundation (ARAID). University 15
of Zaragoza, Zaragoza, Spain16
17
* Corresponding author. Tel.: +34-976733977. E-mail address: eva@icb.csic.es (E. 18
Galvez).19
‡ These authors contributed equally to this work.20
21
22
Keywords: Adhesion molecules, on-column refolding, LFA-123
Page 2 of 33
Ac
ce
pte
d M
an
us
cri
pt
Summary24
The interaction of the adhesion molecule of the immunoglobulin family Intercellular 25
Adhesion Molecule 1 (ICAM-1) with its ligands such the integrins LFA-1 and Mac-1 is 26
crucial for the regulation of several physiological and pathophysiological processes like 27
cell mediated-elimination of tumor or virus infected cells, cancer metastasis or 28
inflammatory autoimmune processes. Thus, production of milligrams of protein is 29
required to perform structural and functional studies as well as design novel approaches 30
to find out new inhibitors of ICAM-1/LFA-1 interaction. Here we report on the 31
production of a recombinant human ICAM-1 chimera comprising the first two 32
extracellular domains of ICAM-1 linked to the Fc fraction of a human IgG1. To this aim 33
we have used a cost-effective method based on the expression of a His-tagged protein in 34
E. coli followed by a single step of refolding and purification on immobilized metal35
affinity columns. This method is able to produce 3mg/liter of bacterial culture in just 72 36
hours with purity greater than 95%. The identity and the native structure of refolded 37
human ICAM-1 chimera were confirmed by biochemical and biophysical studies 38
including SDS-electrophoresis, immunoblot, circular dichroism, isothermal titration 39
calorimetry and fluorescence spectroscopy. Native folding and functional activity of the 40
chimera were further confirmed by different cell biology studies, including B cell 41
adhesion, T cell binding and inhibition of NK cell function. These studies indicate a 42
high biological activity of the protein since it induces a 200-fold increase/mg of protein 43
in B cell adhesion and the Inhibitory Dose 50 to block cell-mediated cytotoxicity is 10 44
pg/effector cell. These analyses show that our protocol is able to produce a recombinant 45
human ICAM-1 chimera fully active and useful to analyse the biological processes in 46
which ICAM-1/LFA-1 interaction is critically involved. 47
48
49
50
51
52
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Introduction53
The intercellular adhesion molecule 1 (ICAM-1) is a membrane glycoprotein, member 54
of the immunoglobulin superfamily (IgSF) and responsible for mediating cell-cell and 55
cell-extracellular matrix interactions [1-3]. In addition, ICAM-1 is the receptor for 56
different human viruses like rhinovirus [4] and coxsackievirus A21 as well as for the 57
malarial parasite Plasmodium falciparum [5-7]. ICAM-1 is formed by 5 extracellular 58
immunoglobulin domains, a hydrophobic transmembrane domain and a short 59
cytoplasmic tail and expressed by several cell types including endothelial and epithelial 60
cells and most types of leukocytes including B and T lymphocytes, NK cells and 61
monocytes [3] [1]. Although the protein is heavily glycosylated, glycosylation does not 62
affect the interaction between ICAM-1 and the integrin LFA-1 [8, 9]. This interaction 63
occurs between domain 1 of ICAM-1 [10] and a metal ion-dependent adhesion site 64
(MIDAS) motif located in the integrin α subunit I domain [11, 12]. Domain 1 of ICAM-65
1 also contains the interaction site with human rhinovirus [13] and Plasmodium 66
falciparum [5] as well as for the extracellular matrix protein fibrinogen [14]. The 67
integrin Mac1 binds to domain 3 of ICAM-1 [8]. ICAM-1 is expressed as a dimer in the 68
plasma membrane of cells and this form binds more efficiently to LFA-1 than 69
monomeric ICAM-1 [15, 16]. However, the crystal structure of dimeric ICAM-1 70
suggests that the dimer is not required for binding of LFA-1 and rhinovirus [17], which 71
occurs by a single molecule of ICAM-1 [18]. In fact monomeric recombinant ICAM-1 72
prevents development of insulitis during autoimmune diabetes [19]. Finally, it has been 73
recently reported that the equilibrium between monomeric and dimeric state regulates 74
the binding to LFA-1 [20]. 75
The interaction of ICAM-1 with LFA-1 regulates several physiological and 76
pathophysiological processes related with lymphocyte extravasation to inflammatory 77
sites and selective entry into lymphoid organs (lymphocyte homing) [3, 21, 22]. In 78
addition, this interaction is critically involved in cell-cell adhesion during antigen 79
presentation and during the recognition and elimination of tumor or virus-infected cells 80
[23]. Apart from its beneficial effect in the elimination of tumor cells and pathogens, 81
ICAM-1/LFA-1 interaction is also involved in diverse pathologies involving 82
inflammation and/or cellular extravasation [24]. It has been shown that specific tumour 83
cells use this interaction to disseminate and spread to other tissues or organs [25-27] and 84
that ICAM-1 expression contributes to drug resistance in multiple myeloma [28]. In 85
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addition, lymphocyte extravasation and accumulation in diverse tissues mediated by 86
LFA-1 is associated with inflammatory diseases like Rheumathoid Arthritis [29], 87
Atherosclerosis [30] and Inflammatory Bowel Disease [31, 32] among others. 88
Altogether, these findings suggest that targeting ICAM-1/LFA-1 interaction may help to 89
inhibit tumor spreading [33]  or to treat inflammatory disorders [33, 34] [35]. 90
Several chromatographic approaches have been previously developed in order to purify 91
and refold recombinant mammal proteins produced in bacterial systems. Among them 92
Immobilised Metal Affinity Chromatography (IMAC) has been proved to be especially 93
useful to purify proteins genetically modified to contain an amino- or carboxy-terminal 94
polyhistidine sequences (His-Tag). This type of affinity chromatography is based on the 95
ability of divalent cations like Cu2+, Co2+ or Ni2+ to bind imidazole groups from 96
histidine residues [36, 37]. In order to bind efficiently the protein multiple histidine 97
groups must located in close proximity. Very few proteins fulfil this prerequisite and, 98
thus, this type of chromatography simplifies the whole purification process. This is 99
especially true if purification is performed under denatured conditions, since the 100
possibility of histidine groups closely located due to the native three-dimensional 101
structure is eliminated. 102
One of the main problems of producing mammal proteins in prokaryotic systems is that 103
proteins are usually expressed as a type of insoluble material known as inclusion bodies. 104
In order to circumvent this problem and get functional proteins in native form in vitro105
refolding must be performed. 106
Among the different protocols used to refold proteins in vitro, [38], it seems that 107
addition of detergents to refolding buffer helps to minimise the formation of aggregates 108
and improves the refold efficiency [39]. A singular advance to avoid the use of large 109
amounts of buffers and time invested in refolding by dilution was the introduction of the 110
on column refolding [40]. Most types of chromatographic methods have been used to 111
refold proteins on columns including size exclusion chromatography [41, 42]112
immobilization on gel matrices [43], hydrophobic interaction chromatography [44], 113
affinity chromatography [45], immobilized liposome chromatography [46] and IMAC 114
[40, 47-50].115
Generation of purified active forms of ICAM-1 is very important to study the above-116
mentioned functions. Specially, the availability of large amounts of active ICAM-1 is 117
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crucial to design efficient and specific approaches to find new inhibitors of ICAM-118
1/LFA-1 interaction. 119
To this aim we have established a simple and fast protocol to generate large quantities 120
of active ICAM-1 chimera in Escherichia coli by reducing the timing and reagents and, 121
thus, improving the efficiency of the process. His-tagged protein is expressed in bacteria 122
as inclusion bodies and refolded and purified in a single step by using Immobilised 123
Metal Affinity Chromatography (IMAC). Our method shows a reduction in total 124
process time of up to 500% and decreases the cost of up to 150% in comparison with 125
refolding by dilution, the most common protocol to purify ICAM-1 in E. coli [9]. The 126
purity of ICAM-1 is greater than 95% and the yield is 3 mg/liter of bacterial culture. 127
Moreover, the activity of ICAM-1 has been proven by using biochemical, biophysical 128
and cell biology models. 129
130
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Materials and methods131
Plasmids and bacterial strains132
Two synthetic cDNAs corresponding to the first two domains (D1D2) of human ICAM1 133
or D1D2 linked to human IgG1 Fc region cloned into pET28a(+) plasmid at NdeI/EcoR1 134
sites (Figure 1) were purchased from GenScript (Piscataway, NJ, USA). Plasmids were 135
transformed into chemically competent BL21 Escherichia coli strain BL21 CodonPlus 136
(Novagen) for high-level protein expression. The proteins expressed by using these 137
constructs contain a 6 histidine-tag at the N-terminal site.138
139
Expression and Purification of D1D2Fc and D1D2140
Bacterial cultures containing pET28a-D1D2Fc or pET28a-D1D2 were grown at 37ºC 141
until the optical density (OD) at 600 nm reached 0.6-0.8. Subsequently, protein 142
expression was induced by adding isopropyl-beta-D-1-galactopyranoside (IPTG) to a 143
final concentration of 1mM for 3 h at 37ºC. After protein induction cells were recovered 144
by centrifugation at 17,700 g for 8 min at 4ºC. Proteins were solubilised from inclusion 145
bodies by resuspending the cell pellets in 6 M guanidine hydrochloride (GdmCl) at 146
room temperature with gently shaking overnight. Subsequently, cell suspension was 147
centrifuged at 48,400 g for 30 min at 4ºC to pellet cellular debris. Supernatants 148
containing the soluble proteins were then recovered and incubated for 1 hour at room 149
temperature with Ni-NTA resin (Qiagen, Hilden, Germany) to allow the polyhistidine 150
tag to bind to the resin. After centrifugation at 157 g for 2 min, most of the supernatant 151
was carefully removed and then resin was resuspended in the remaining supernatant, 152
transferred to a gravity-flow column and allowed to settle. 153
On-column renaturation and purification was performed by several changes of buffers 154
following a modified protocol based on that described by Oganesyan [47]. First, the 155
column was washed using the denaturing buffer containing 20mM imidazole to remove 156
non-specifically-bound contaminants and mercaptoethanol 10mM to reduce disulfide 157
bonds. Then, renaturation was carried on using buffer A (20mM Tris-HCl pH 8.0, 0.1M 158
NaCl). In the first step, the column was washed with 10-column volumes (CV) of buffer 159
A containing 0.1% Triton X-100 and mercaptoethanol 10mM. Next, resin was washed 160
with 10 CV of buffer A containing 5mM Methyl-β-cyclodextrin (Sigma, St.Louis, 161
Missouri, USA) to remove detergent from the protein-detergent complex and to allow 162
the protein to refold. The last wash before elution was performed with 20mM Tris-HCl 163
pH 8.0, 0.5M NaCl to remove remaining impurities and Methyl-β-cyclodextrin. All 164
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steps were performed in the presence of a cocktail of protease inhibitors (Roche, Basel, 165
Switzerland). Refolded protein was eluted with buffer A containing 1 M imidazole and 166
protein concentration was measured using a spectrophotometer (NanoView, Healthcare, 167
Waukesha, WI, USA). Fractions containing the highest levels of protein were passed 168
through a desalting column (PD-10 Desalting Columns, GE Healthcare, Waukesha, WI,169
USA) following manufacturer’s instructions and the protein was recovered in phosphate 170
buffered saline (PBS). Protein concentration was adjusted to 500µg/ml by ultrafiltration 171
using 10,000 MWCO Centrifugal Filter Units (Amicon, Millipore, Billerica, MA, USA) 172
and stored at -20ºC. The level of protein expression after IPTG induction and the quality 173
of purified proteins was evaluated by sodium dodecyl sulfate polya rylamide gel 174
electrophoresis (SDS–PAGE) under reducing conditions and staining with Coomassie 175
Blue.176
177
Western blot analysis178
Purified D1D2Fc and D1D2 was analysed by western blotting under reducing conditions 179
by using a mouse mAb against human CD54/ICAM1 (clone 28/CD54; BD bioscience, 180
San Jose, CA, USA; dilution 1:1000) or a mouse mAb against HisTag (Novagen, 181
Madison, WI, USA; dilution 1:1000). Then, the blot was stained with peroxidase-182
conjugated secondary antibodies, rabbit anti-mouse (Amersham, Piscataway, NJ, USA; 183
dilution 1:10000). Subsequently, a peroxidase substrate for enhanced 184
chemiluminescence (ECL) from Pierce (Rockford, IL, USA) was used for detection.185
186
Circular dichroism spectroscopy187
Secondary structure of proteins was examined using circular dichroism (CD) in a 188
Chirascan spectropolarimeter (Applied Photophysics). Spectra were recorded in the far 189
ultraviolet region (200nm-250nm) with a protein concentration of 6M in PBS190
(Phosphate buffered saline) and a scan rate of 1 nm/s. The temperature was controlled 191
by a Peltier controller. It was employed a quartz cuvette 0.1cm path length. 192
193
Fluorescence Spectroscopy194
Protein samples were characterized by fluorescence spectroscopy using a Cary Eclipse 195
spectrofluorometer (Varian, Palo Alto, CA, USA) thermostated by a Peltier temperature 196
control unit, employing either the fluorescence emission from the internal tryptophan 197
residues or from the ANS (8-anilino-1-naphthalenesulfonic acid) extrinsic probe. When 198
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convenient, the fluorescence intensity at a certain wavelength, I, or the average energy 199
of the spectrum:200
201
  
Average Energy !
I! e
! 1
n
!
I!
n
!202
203
was considered as the reporting signal. Protein samples were excited at 290 nm and 390 204
nm when tryptophan and ANS spectra were recorded, respectively, with a slit width of 5 205
nm.206
Thermal unfolding assays were conducted in order to assess the structural stability of 207
the proteins. An unfolding model considering an intermediate partially folded state was 208
employed: 209
210
(T)(T)IF(T)(T)IF(T)(T)IFS(T) UUIINN 211
212
where T is the absolute temperature; S(T) is either the fluorescence intensity at a certain 213
wavelength or the average energy of the spectrum; IN, II and IU are the intrinsic 214
contributions to the fluorescence of each conformational state, that are assumed to 215
exhibit a linear dependency with the temperature:216
217
Tba(T)I XXX 218
219
and FN(T), FI(T) and FU(T) are the fraction population of each conformational state 220
(native, intermediate and unfolded) and can be expressed in terms of the equilibrium 221
constants associated with each conformational transition, K1(T) and K2(T):222
223
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The equilibrium constants are also temperature dependent:226
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where R is the ideal gas constant, Tmi is the unfolding (or mid-transition) temperature, 230
Hi is the unfolding enthalpy, and CPi is the unfolding heat capacity for each transition 231
i. Non-linear square regression data analysis implemented in Origin (OriginLab) 232
provides the unfolding parameters (Tmi, Hi, and CPi) for both proteins, D1D2Fc and 233
D1D2.234
235
Isothermal titration calorimetry236
The ability of D1D2Fc to interact with a peptide derived from its natural ligand LFA-1 237
was analysed by isothermal titration calorimetry (ITC) on a VP-ITC calorimeter 238
(MicroCal) at 25 °C. The peptide sequence was DSGNIDAAKD corresponding to 239
aminoacids 244-253 from LFA-1 [51]. 2.2 ml of a 12 µM solution of D1D2Fc and 0.6 ml 240
of a 150 mM solution of peptide were prepared in PBS and degassed with a vacuum 241
pump for 10 min. Protein solution was carefully injected into the cell previously washed 242
with PBS. Each assay consisted of a series of 28 injections of peptide solution of 10 ul 243
each (with a 4-l first onjection) at 400 s intervals under constant stirring (459 rpm). 244
The thermal power required to keep the cell at a constant temperature is measured, so 245
that it provides the heat associated with each ligand injection after integrating the signal 246
over time. The thermodynamic parameters of protein-peptide interactions (affinity, 247
enthalpy and entropy changes) as well as the stoichiometry were estimated by using 248
nonlinear regression analysis. Data were analyzed using the software developed and 249
implemented in Origin 7.0 (OriginLab).250
251
Cell Adhesion assay252
The ability of ICAM1 chimera (D1D2Fc) to induce cell adhesion of non-adherent cells 253
expressing LFA-1 was analysed by using the EBV transformed human B 254
lymphoblastoid cell line R69, a generous gift from José A. López de Castro [52].255
Adhesion assay was performed in flat bottom 96-well plates in which different amounts 256
of ICAM-1 chimera or human IgG1 (Fc control) had been previously immobilized for 257
18h at 4ºC. R69 human cells were washed twice in DMEM medium supplemented with 258
10% fetal bovine serum, 2 mM L-glutamine and antibiotics (penicillin 100 U/ml, 259
streptomycin 100 μg/ml) and resuspended at a final concentration of 106 cells/ml. Then, 260
LFA-1 expression was induced by incubating cells with 10 ng/ml PMA for 2 hours at 261
37°C [53]. Subsequently, 1x105 cells were added to each well and incubated at 37°C for 262
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4 hours. To quantify the number of adherent cells a modification of the MTT 263
colorimetric test designed by Mosmann [54] was used. 264
265
Flow cytometry (FACS)266
The ability of D1D2Fc to quantify the expression of LFA-1 on cells was analysed by 267
flow cytometry in the human T leukemia cell line Jurkat (clon E6-1, ATCC). Jurkat 268
cells were incubated with different concentrations of D1D2Fc or human IgG1 control at 269
4°C for 30 min, washed twice with FACS buffer (PBS, 5% FCS, 0,1% NaN3) and then 270
incubated with PE-conjugated goat anti-human IgG (Fc fragment specific; Jackson 271
ImmunoResearch). After a washing step with FACS buffer, cells were analysed by 272
FACS using a FACSCalibur with CellQuest Pro software (BD).273
274
Cytotoxicity assay275
The effect of D1D2Fc and D1D2 on ICAM-1/LFA-1 depe dent cell-cell contact was 276
analysed by performing a cell cytotoxicity assay using human primary NK cells and the 277
NK-cell sensitive human leukemia K562. Primary human NK cells were generated by 278
culturing human peripheral blood mononuclear cells (PBMCs) with mitomycin C 279
inactivated R69 cells for 5 days as previously described [55]. Then, NK cell fraction 280
was enriched by MACS using anti-CD56 antibodies as previously described [56]. Cell 281
cytotoxicity induced by NK cells on K562 was analyzed by flow cytometry as 282
previously described [56]. Briefly, NK cells were preincubated with medium alone or in 283
the presence of different amounts of D1D2Fc , D1D2 or human IgG1 control for 15 min 284
at 37ºC. Then, they were added to K562 cells at different e:t cell ratio for 4h at 37ºC, 285
5% CO2. Subsequently, phosphatidylserine exposure and AAD uptake were analyzed 286
by FACS using the annexin-V/AAD kit from BD Pharmingen.287
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Results and discussion288
289
Expression of recombinant proteins290
First we have analysed that E. coli BL21-Codon plus cells transformed with pET28a-291
D1D2Fc or pET28a-D1D2 overexpressed the respective proteins after induction with 292
IPTG. As shown in Figure 2A, the expression of two proteins was clearly increased 293
after 2 and 3 hours of induction. The approximate MW of these proteins was 50 kDa 294
(lanes 2 and 3) and 25 kDa (lanes 5 and 6), which matched well with the theoretical 295
MWs of D1D2Fc and D1D2, respectively. In contrast, non-induced cells did not express 296
the proteins (lanes 1 and 4). The highest level of expression was found at 3 hours and 297
longer induction times (4 and 24h) did not increase that level. Thus, we chose this time-298
point in the subsequent experiments.299
300
Purification of recombinant proteins301
Ni-NTA affinity chromatography was applied for the purification of D1D2 and D1D2Fc 302
poly-histidine tagged proteins. Poly-histidine tags form high affinity complexes with 303
immobilized divalent metal ions (such as Ni2+ or Co2+), even in the presence of high 304
concentrations of chaotropic agents (e.g., urea or GdmCl), thereby allowing isolation of 305
tagged protein from a crude cellular extract [36, 37, 57]. In addition, these properties 306
allow to refold denatured proteins by changing the buffer composition flowing through307
the column [40, 47-50]. Most of D1D2Fc and D1D2 exist in the bacterial cells in the form 308
of inclusion bodies that were solubilized by resuspending bacterial pellets in 6M 309
GdmCl. Soluble proteins were incubated with the Ni-NTA resin slurry to allow binding 310
of the poly-histidine-tagged proteins and folded as indicated in methodological section.311
As shown in Figure 2B, non-bound proteins were washed out during the first two steps 312
of purification (lanes 3 and 4). These fractions also contained some D1D2Fc protein, 313
although at very low levels. Unbound proteins were not detected anymore in fractions 314
corresponding to the folding steps (lanes 5 and 6).  After folding the bound proteins, 315
they were eluted by using imidazole. Most of D1D2Fc protein eluted in the early316
fractions (Figure 2B, lanes 8-12) which contained a small amount of proteins of lower 317
MW, suggesting that either contaminating proteins co-eluated with D1D2Fc or some 318
protein degradation ocurred during the purification process. In order to confirm the 319
identity of the purified protein and of the low MW forms, we performed immunoblot 320
using mAbs specific for ICAM-1 (Figure 2C, lane 1) or for the poly-histidine tag 321
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(Figure 2C, lane 2). As shown in the blots a single band corresponding to D1D2Fc was 322
detected by using anti-ICAM-1 mAb confirming the identity of the purified protein. In 323
contrast, several bands were detected with the anti-HisTag antibody. The pattern of 324
bands detected by this mAb matched those observed by Coomassie Blue staining 325
(Figure 2B), confirming that the low MW proteins contains a poly-histidine tag and, 326
thus, correspond to short forms of our fusion protein. Since poly-histidine tag is placed 327
at the N-terminal site, this result indicates that degradation of the protein occurs at the 328
C-terminal site where the Fc fraction is located. Moreover, it suggests that the epitope 329
recognised by the anti-ICAM-1 mAb is missed in the degraded proteins. Anyway, the 330
level of degradation is minimal since the intensity of the 50 KDa band corresponding to 331
D1D2Fc was much stronger than that of the lower bands. 332
Similar results were found when D1D2 protein was purified (Figure 2D and 2E). 333
However, no degradation products were observed in the purified fraction, confirming 334
that the residual degradation of the D1D2Fc chimera occurred by the Fc fraction. This 335
result is not surprising since it is known that Fc regions are especially susceptible to the 336
action of specific proteases like pepsin-like proteases. However, this effect has been 337
minimised by including general protease inhibitors during the purification process.338
Altogether, the results indicate that the purified protein corresponds to the recombinant339
ICAM-1 D1D2Fc chimera and degradation is hardly observed. The yield obtained by 340
using this protocol is around 3 mg per liter of bacterial culture and the entire process 341
took just 72 hours from bacterial cultures to purified protein. Of note, the purification of 342
other recombinant proteins using redolding by dilution takes about 14 days in our 343
laboratory.344
345
Circular dichroism 346
Next we have analysed by circular dichroism (CD) whether purified ICAM-1 D1D2Fc 347
chimera is properly folded and presents the expected secondary structure. ICAM-1 348
belongs to the IgSF and each of its domains presents a typical Ig-like structure 349
characterised by the presence of β-sheets [58]. Dichroism spectra in the far ultraviolet350
region are primarily due to the amide bonds linking the amino acid residues. The351
asymmetry of these chromophores is due to the spatial arrangement of the main chain of352
the protein, thus, the circular dichroism signals can be interpreted in terms of the 353
content of secondary structure present, i.e. the percentage of residues found in some354
structural conformation (α helix, β sheets, turns and other structural types). 355
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As shown in Figure 3A the CD spectrum of D1D2Fc shows a single broad negative 356
ellipticity centered at approximately 205 nm. This result indicates that the protein357
predominatly contains β sheets or turns as secondary structures and, thus, that the 358
folding protocol renders a protein with the expected secondary structure.359
360
Fluorescence spectroscopy 361
Both D1D2Fc and D1D2 show a fluorescence spectrum with two maxima around 330 nm 362
and 375 nm, in agreement with these two proteins containing several tryptophan 363
residues (Figure 3B, i).364
In order to test the structural integrity of the proteins, fluorescence thermal 365
denaturations were performed (Figures 3B, ii-vi). Unfolding parameters for D1D2Fc 366
following the thermal denaturation either by intrinsic tryptophan fluorescence or 367
extrinsic ANS fluorescence provided similar results (Figures 3B, ii and iv, Table 1). 368
However, for D1D2 only ANS fluorescence data showed a clear unfolding curve (Figure 369
3B, vi). Two transitions can be clearly observed for the unfolding behavior of D1D2Fc, 370
whereas for D1D2 was not so evident. However, analysis of D1D2 unfolding employing a 371
model considering a single transition provided illogical results (e.g. negative unfolding 372
enthalpy, which is impossible for a temperature-driven process). Using the average 373
energy of the spectrum presents two advantages: 1) signal is concentration-independent; 374
and 2) global changes in the spectrum are taken into account, that could be overlooked 375
when just paying attention to a certain wavelength. Because both proteins, D1D2Fc and 376
D1D2, contain several tryptophan residues, interpretation of the results obtained when 377
the intrinsic tryptophan fluorescence was employed as a reporter signal was somewhat 378
difficult.379
According to the data analysis, D1D2Fc showed two transitions with Tm’s at 40C and 380
70C, and unfolding enthalpies of 20 and 50 kcal/mol, respectively. Deletion of the Fc 381
domain leads to a slight stabilization of the less stable region and a destabilization of the 382
more stable region (Table 1).383
384
Isothermal titration calorimetry385
CD and thermal denaturation data indicate that ICAM-1 chimera presents a proper 386
secondary and tertiary structure folding. However, this does not mean that the protein is 387
functionally active and able to recognise its natural ligands. To test D1D2Fc activity we 388
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have analysed the interaction of this protein with a peptide derived from its natural 389
ligand LFA-1 (DSGNIDAAKD) by isothermal titration calorimetry. 390
As shown in Figure 4 this peptide presents a high affinity for D1D2Fc (dissociation 391
constant Kd of 0.090 M) as expected since its sequence is derived from the integrin I 392
domain contained in the α subunit of LFA-1, the principal binding site for D1 of ICAM-393
1. This result agrees with previous findings showing that this peptide inhibits the 394
homotypic T cell adhesion mediated by ICAM-1/LFA-1 interaction [51]. In addition, it 395
indicates that D1D2Fc is fully functional in cell-free models and able to bind a peptide 396
derived from LFA-1.397
Moreover, our data provide for first time the dissociation constant for ICAM-1 and a 398
peptide agonist. The value obtained (90 nM) is lower than that previously found for the 399
interaction between soluble monomeric ICAM-1 and the high affinity form of its natural 400
ligand LFA-1 (Kd: 500 nM) [59] and higher than that found for dimeric ICAM-1 (Kd: 1-401
10 nM) [15, 16]. This result provides the biophysical explanation to the capacity of the 402
peptide to block lymphocyte intercellular adhesion s previously reported [51]. In 403
addition, it may help to design novel peptide inhibitors to target this interaction and 404
modulate the immune response [60].405
406
Binding of ICAM-1 chimera to B and T cell-associated LFA-1407
ITC experiments indicate that D1D2Fc contains the proper folded domains involved 408
in the interaction with a specific sequence derived from integrin I domain of LFA-1. 409
However, short peptides are lineal aminoacid sequences that do not completely mimic 410
the interaction among proteins containing a three-dimensional spatial structure. Thus, to 411
proves that D1D2Fc is active and useful to analyse processes in which ICAM-1/LFA-1 412
interaction is involved, we have analysed the ability of the purified protein to bind the 413
native form of LFA-1 expressed on the plasma membrane of lymphoid cells. To this 414
aim we tested the ability of immobilised D1D2Fc to adhere LFA-1 expressing B cells 415
and the interaction of D1D2Fc and LFA-1 in T cells by flow cytometry (Figure 5).416
As showed in Figure 5A, D1D2Fc is able to mediate the adhesion of activated B 417
lymphocytes showing the highest activity at a concentration of 50 μg/well. Cells 418
incubated with medium alone or in wells coated with IgG1 show extensive clumping 419
and no adherent cells are seen. In contrast, cell clumping is much more reduced in wells 420
coated with D1D2Fc and several cells with fibroblast-like morphology can be detected. 421
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The quantification of cell adhesion results in a 10-fold increase related to the negative 422
IgG control. 423
The activity of this chimera to promote B cell adhesion was lower than that found 424
by using a chimera expressing the 5 domains of ICAM-1 (data not shown). It has been 425
previously reported that D1 presence on a single molecule of ICAM-1 is enough to bind 426
LFA-1 [17] [18]. However, the presence of the 5 domains of ICAM-1 provides a better 427
adhesion as previously suggested [15, 16]. Another explanation could be that the B cells 428
used in this assay expresses Mac-1 that would bind through the D3 domain absent in 429
D1D2Fc.430
Next, we tested if this chimera was also useful to analyse the expression of LFA-1 431
in the cell membrane by flow cytometry. To this aim we have used the human T 432
leukemia Jurkat. As shown in Figure 5B the percentage of positive cells increases as it 433
increases the amount of chimera added. The performance of this chimera (1 g/105434
cells) to recognise its specific ligand (LFA-1) is similar to that of other chimeras 435
expressed and purified in native form in eukaryotic cells and used to analyse specific 436
ligands in Jurkat cells like NKG2D-Fc (data not shown). Incubation with an antiCD54 437
(ICAM-1) antibody blocked binding of the chimera (data not shown) showing that 438
D1D2Fc is able to specifically bind to Jurkat cells through its natural ligand LFA-1.439
As indicated above this result is supported by previous findings indicating that the 440
presence of D1 is enough to bind LFA-1.441
442
Blocking of NK-cell mediated cytotoxicity 443
The interaction of ICAM-1, expressed on tumor or virus infected cells, with LFA-1, 444
expressed on the membrane of Natural Killer (NK) cells, modulates the formation and 445
signalling of the NK immunological synapse [61].  This process is critically involved in 446
the elimination of tumor and/or virus-infected cells by NK cells [62]. In order to analyse 447
whether D1D2Fc was able to interfere with the cytotoxic function of NK cells, we have 448
tested the ability of this chimera to inhibit the elimination of tumor cells by human NK 449
cells. As can be seen in Figure 6 incubation with increasing amounts of D1D2Fc 450
completely blocked cell death induced by human NK wells on the human leukemia 451
K562. Control human IgG1 had no effect on this process (data not shown). Importantly, 452
inhibition was not due to the presence of the Fc region, which is known to bind and 453
activate specific receptors in NK cells, since purified D1D2 showed a similar activity. 454
Similar results were found by using the leukemic target cells Raji, Jurkat or U937 (data 455
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not shown). These results indicate that this chimera can also be used to study the 456
processes in which NK cells maybe involved. Moreover, it indicates a good biological 457
activity of the chimera since 100 pg of protein is able to completely block cell death 458
exerted by one NK cell. 459
460
Conclusions461
To our knowledge, this is the first report on the purification of an active form of 462
ICAM-1 by using a simple and fast bacterial-based method more advantageous than 463
mammalian models, which are very expensive and often difficult to set-up, or than other 464
traditional folding protocols, which are time consuming and require large amounts of 465
reagent such a refolding by dilution. In comparison with refolding by dilution, the most 466
common protocol to purify ICAM-1 in E. coli [9], our method shows a reduction in total 467
process time of up to 500% and decreases the cost of up to 150%. If we compare it with 468
mammalian models like HEK or COS cells, the reduction in time and money is much 469
higher. These chimeras are of special interest to study cell adhesion assays, expression 470
of functional ligands on cells by flow cytometry, blocking cell-cell adhesion mediated 471
processes as well as quantification of soluble ligands by ELISA. Our protocol has 472
proven useful in order to analyse several physiological processes in which ICAM-473
1/LFA-1 interaction is critically involve . Moreover, it is fast and cheap, providing a 474
perfect platform in order to develop large-scale inhibitor screenings or in vivo models of 475
ICAM-1 associated pathologies, which are hard to set-up by using commercial purified 476
proteins or other expression systems. 477
478
479
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491
Table 1. Thermodynamic parameters for the unfolding of D1D2Fc and D1D2 obtained 492
by following the thermal unfolding by intrinsic tryptophan or ANS fluorescence.493
494
Tm1 (
oC) H1 (kcal/mol) Tm2 (oC) H2 (kcal/mol)
D1D2Fc (Trp) 39.1  0.2 20.0  0.3 69  1 51  1
D1D2Fc (ANS) 40.0  0.4 19.5  0.4 70  1 49  1
D1D2 (ANS) 46  1 23  1 65  1 27  1
495
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Figure legends496
Figure 1. Schematic representation of the aminoacid sequences of the proteins 497
expressed by using the constructs pET28a-D1D2Fc and pET28a-D1D2. Numbers indicate 498
the corresponding aminoacids in human ICAM-1 sequence. Histidine tag (H), domain 1 499
(D1), domain 2 (D2), Linker (L), human IgG1 Fc region (Fc).500
Figure 2. Analyses of the expression and purification of D1D2Fc D1D2 in E. coli by 501
SDS-PAGE electrophoresis and western blot. Bacteria were transformed by using 502
pET28a-D1D2Fc or pET28a-D1D2 constructions and proteins were expressed and 503
purified as described in materials and methods. A analysis of protein overexpression in 504
bacteria by Coomassie Blue staining after SDS-PAGE. M: MW markers; 1,4: non-505
induced transformed bacteria; 2, 3, 5, 6: bacteria induced with IPTG for 2h (2 and 5) or 506
3h (3 and 6). B and D, analysis of protein refolding and purification by Coomassie Blue 507
staining after SDS-PAGE. M: MW markers; 1: induction with IPTG; 2-4 non-bound 508
proteins; 5-6: folding steps; 7-15: elution with Imidazole. C and E, purified proteins 509
were separated by SDS-PAGE and analysed by western blot using antibodies specific 510
against ICAM-1 (lane 1) or poly-histidine tag (lane 2). 511
Figure 3. Spectroscopic structural characterization. A, Circular Dichroism spectra of 512
D1D2Fc recorded in the far ultraviolet region (200nm-250nm). B, Thermal denaturation. 513
i) Tryptophan fluorescence emission spectra of D1D2Fc (protein 2 M in PBS buffer). 514
Inset: Tryptophan fluorescence emission spectra of D1D2 under the same conditions; ii), 515
Thermal unfolding of D1D2Fc followed by tryptophan intrinsic fluorescence emission at 516
330 nm. The temperature dependence of the fluorescence intensity at 330 nm was fitted 517
to a 2-transition unfolding model; iii) ANS fluorescence emission spectra of D1D2Fc 518
(protein 2 M and ANS 100 M in PBS buffer); iv) Thermal unfolding of D1D2Fc 519
followed by ANS fluorescence. The temperature dependence of the fluorescence 520
average energy of the ANS spectrum was fitted to a 2-transition unfolding model. A 521
similar result was obtained when the temperature dependence of the ANS fluorescence 522
emission at 470 nm was fitted to a 2-transition unfolding model; v) ANS fluorescence 523
emission spectra of D1D2. Protein 2 M and ANS 100 M in PBS buffer; vi) Thermal 524
unfolding of D1D2 followed by ANS fluorescence. The temperature dependence of the 525
fluorescence average energy of the ANS spectrum was fitted to a 2-transition unfolding 526
model. A similar result was obtained when the temperature dependence of the ANS 527
fluorescence emission at 470 nm was fitted to a 2-transition unfolding model.528
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Figure 4. Interaction of LFA-1 peptide with D1D2Fc by isothermal titration 529
calorimetry (ITC). Purified D1D2Fc (12 M) was titrated with a peptide derived from 530
the binding site of LFA-1 (150 M). The assay was performed in PBS buffer at 25C. 531
The non-linear regression analysis provided a dissociation constant of 91 nM.532
Figure 5. Binding of D1D2Fc to cell-associated LFA-1. A, B cell adhesion assay. 533
Different amounts of D1D2Fc or human IgG1 control were immobilised in 96 well 534
plates o.n. at 4ºC. After washing out non-bound protein, the PMA-activated R69 B cell 535
line was added by triplicates and cell adhesion was analysed by MTT as described in 536
materials and methods. Quantification of cell binding was represented as fold increase 537
with respect to the human IgG1 control. B, analysis of D1D2Fc binding to LFA-1 in 538
Jurkat cells by flow cytometry. Different amounts of D1D2Fc or human IgG1 control 539
were incubated with Jurkat cells. After washing out non non-bound proteins cells were 540
incubated with PE-conjugated goat anti-human IgG Fc Ab and analysed by flow 541
cytometry. A representative histogram is shown. Numbers correspond to the % of cells 542
as gated by the vertical bars. Black: goat anti-human IgG; Grey: human IgG1; Colour: 543
D1D2Fc (red: 5 g; green: 10 g; blue: 15 g). Values in the graph are represented as 544
mean+/- SEM of 3 independent experiments performed by duplicate. Statistical analyses 545
were done with two-way ANOVA with Bonferroni post-test by comparing IgG with 546
D1D2Fc. ns: not statistically significant; *** p<0.001.547
Figure 6. D1D2Fc inhibits NK-cell mediated cytotoxicity on tumor cells. MACS-548
enriched human NK cells, previously stained with the fluorescence dye CFSE, were 549
incubated with K562 cells at 1:1 effector:target ratio (1x105 cells) for 4h in the presence 550
or absence of different amounts of D1D2Fc, D1D2 or human IgG1 control. Subsequently, 551
cell death was analysed by measuring PS translocation by flow cytometry in the CFSE 552
negative cell population (K562) as described in materials and methods. Values are 553
represented as mean+/- SEM of 2 different experiments. Statistical analyses were done 554
with two-way ANOVA with Bonferroni post-test by comparing IgG, D1D2 and D1D2Fc 555
with control. ns: not statistically significant; *** p<0.001.556
557
558
559
560
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- we have established a fast and cost-effective method to produce recombinant human 
ICAM-1  
- ICAM-1 presents a proper folding as revealed by analyses of secondary and tertiary 
structure  
- purified ICAM-1 is highly active and proves useful for biochemical, immunological 
and cell biology studies.  
- ICAM-1 has been used to calculate the dissociation constant of peptide inhibitors used 
to treat inflammatory disorders 
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